Application Note

A Human HTS Platform For Assessing Gastrointestinal Toxicity (GIT) Risk In Early Development

Source: Altis Biosystems
intestine iStock-1138681666

GI tract represents the most common target organ of adverse drug reactions (35% of clinical AEs). Clinical safety failures are only predicted by nonclinical studies 25% of the time. Why?

  • Lack of predictable in vitro models
  • Rodents show low concordance (42%) with human clinical outcomes4
  • Non-human primates are more predictive, but limited by cost, throughput, and ethics (reserved for lead)4

There is a significant unmet need for human models of GI risk assessment that can be utilized for drug optimization in early development. We review a solution with high quality Human GI stem cell platform, diverse donor demographics (age, race, sex), and rigorous quality control of all cell lots.

VIEW THE APPLICATION NOTE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online